[1]Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention)[J]. J Am Col Cardiol, 2014, 63(7): 619-629.
[2]Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials[J]. Lancet, 2012, 379(9826): 1602-1612.
[3]Song Y, Tang XF, Zhang JH, et al. TCT-206 effect of the α2A-adrenergic receptor genetic variants on platelet reactivity and adverse clinical events in Chinese patients with dual antiplatelet therapy after percutaneous coronary intervention[J]. J Am Col Cardiol, 2015, 66(15): B79.
[4]Amut E, Umrr Y, Jia DM, et al. Practice and experience of developing drug administration in primary hospital[J]. Chin Pharm,2015, 50(7): 650-652.
[5]Luo M, Wu B, Wu FB, et al. Impact of pharmacist-participa-ted anticoagulation service on warfarin therapy management:A systematic review[J]. Chin Pharm J, 2015, 50(61): 554-558.
[6]Lin JP. According to the norm of heparin clinical application[J]. Chin J MOD Drug Appl, 2011, 5(20): 65-66.
[7]Zhang QX, Wang YL. Kidney damage associated with low-dose of enteric-coated aspirin tablets in 16 patients[J]. ADRJ, 2004, 6(2): 82-82.
[8]Stankovic I, Vlahovic-Stipac A, Putnikovic B, et al. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis[J]. Clin Ther, 2010, 32(5): 909.
[9]刘艺平, 徐萍, 李焕德. 氯吡格雷的药学监护[C]. 2010 年中国药学大会暨第十届中国药师周论文集, 2010.
[10]韩雅玲, 王守力, 李毅, 等. 急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J]. 中国介入心脏病学杂志, 2005, 13(1): 9-12.
[11]Mcquaid KR, Laine L. System atic review and metaanalysis of adverse even ts of lowdose asp irin and clop idogrel in random izedcon trolled trials[J]. Am J Med, 2006, 119 (8): 624-638.
[12]Seshasai SRK, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials[J]. Arch Inter Med, 2012, 172(3): 209-216.
[13]徐佑龙, 刘宗军. 不同中药在抗血小板药物抵抗患者中的研究[J]. 长春中医药大学学报, 2014, 30(1): 34-36.
[14]Fung ZH, Yu TL. Aspirin on renal damage in primary hypertension, 186 cases of clinical analysis[J]. J Huaxi Med, 1999, 14(3): 307. |